Dr Reddy's Laboratories Gross Profit 2010-2024 | RDY

Dr Reddy's Laboratories annual/quarterly gross profit history and growth rate from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Dr Reddy's Laboratories gross profit for the quarter ending June 30, 2024 was $0.556B, a 15.35% increase year-over-year.
  • Dr Reddy's Laboratories gross profit for the twelve months ending June 30, 2024 was $2.037B, a 10.17% increase year-over-year.
  • Dr Reddy's Laboratories annual gross profit for 2024 was $1.963B, a 15.74% increase from 2023.
  • Dr Reddy's Laboratories annual gross profit for 2023 was $1.696B, a 12.99% increase from 2022.
  • Dr Reddy's Laboratories annual gross profit for 2022 was $1.501B, a 6.53% increase from 2021.
Dr Reddy's Laboratories Annual Gross Profit
(Millions of US $)
2024 $1,963
2023 $1,696
2022 $1,501
2021 $1,409
2020 $1,247
2019 $1,207
2018 $1,172
2017 $1,208
2016 $1,393
2015 $1,370
2014 $1,264
2013 $1,112
2012 $1,048
2011 $904
2010 $808
2009 $
Dr Reddy's Laboratories Quarterly Gross Profit
(Millions of US $)
2024-06-30 $556
2024-03-31 $489
2023-12-31 $506
2023-09-30 $486
2023-06-30 $482
2023-03-31 $412
2022-12-31 $489
2022-09-30 $466
2022-06-30 $329
2022-03-31 $355
2021-12-31 $385
2021-09-30 $416
2021-06-30 $346
2021-03-31 $361
2020-12-31 $363
2020-09-30 $357
2020-06-30 $328
2020-03-31 $232
2019-12-31 $334
2019-09-30 $392
2019-06-30 $288
2019-03-31 $318
2018-12-31 $288
2018-09-30 $299
2018-06-30 $302
2018-03-31 $281
2017-12-31 $332
2017-09-30 $295
2017-06-30 $264
2017-03-31 $315
2016-12-31 $322
2016-09-30 $301
2016-06-30 $269
2016-03-31 $297
2015-12-31 $359
2015-09-30 $377
2015-06-30 $361
2015-03-31 $353
2014-12-31 $355
2014-09-30 $333
2014-06-30 $347
2014-03-31 $317
2013-12-31 $346
2013-09-30 $312
2013-06-30 $252
2013-03-31 $312
2012-12-31 $271
2012-09-30 $289
2012-06-30 $243
2012-03-31 $311
2011-12-31 $312
2011-09-30 $233
2011-06-30 $241
2011-03-31 $230
2010-12-31 $233
2010-09-30 $233
2010-06-30 $192
2010-03-31 $160
2009-12-31 $191
2009-09-30 $182
2009-06-30 $213
2009-03-31 $269
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $12.399B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00